You just read:

Janssen Submits Application to U.S. FDA Seeking First-in-Class Approval of TREMFYA® (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 16, 2019, 07:30 ET